ABCC2 and non-small cell lung carcinoma: Concerning clinical efficacy, previous studies have shown that patients with the ABCC2 c.-24T homozygous genotype had significantly better response rates and progression-free survival in non-small-cell lung cancer patients treated with irinotecan and cisplatin [42].